Home

4+7 药品带量采购试点执行以来,药品价格切实降低,同时也对药品的供应保障提出了挑战。带量采购是否能在全国全面推行,是否有条件将带量采购延伸到更多品类,医药企业应该如何应对,都是值得探讨和深思的话题。上海美国商会将于2019 年 8 月 22举办带量采购研讨会,邀请来自医药政策学者、行业研究和医疗企业的代表,帮助医疗从业人员及会员企业更为深入地理解政策动向及实施要求。


AmCham Healthcare Committee will hold a discussion on the impact of the volume-based procurement in "4+7 cities" on Aug 22nd, from 12:30-15:20. Speakers include representatives from a healthcare policy research institute, a healthcare consultancy, and pharmaceutical and medtech companies.


活动日程Agenda


12:30 签到

Registration


12:55 开场

Opening Remarks


13:00 上海市卫生和健康发展研究中心主任 金春林——国家"4+7"药品集中带量采购实践与展望

Practice and Outlook for the Volume-Based Procuremnt of Drugs in "4 + 7 Cities" by Jin Chunlin


14:00 毕马威全球战略咨询生命科学行业副总监 许宗迪——"4+7"带量采购的行业影响及应对

Industrial Impact of Volume-based Procurement of Drugs in "4 + 7 Cities" and the Coping Strategy by Jessica Xu


14:20 主题演讲:百时美施贵宝(中国)高级副总裁 中国市场准入总裁 傅旭东

Presentation by Xudong Fu, Vice GM, President of Market Access China, BMS China


14:40 专题讨论 (BD大中华区公共事务及传播部高级总监 韦春艳主持)

Panel Discussion Moderated by Anita (Chunyan) WEI


15:10 观众提问

Audience Q&A


15:20 活动结束

Event Ends



嘉宾Speakers


  • 上海市卫生和健康发展研究中心(上海市医学科学技术情报研究所)主任 金春林

Jin Chunlin, Director of Shanghai Health Development, Research Center (Shanghai Medical Information Center)

  • 百时美施贵宝(中国)高级副总裁 中国市场准入总裁 傅旭东

Xudong Fu, Vice GM, President of Market Access China, BMS China

  • 阿斯利康市场准入战略及卓越运营执行总监 曹宇静

Christina Cao, Executive Director, Market Access Strategy & Excellence, AstraZeneca China

  • BD大中华区公共事务及传播部高级总监 韦春艳

Anita (Chunyan) WEI, Public Affairs & Communications Director, BD Greater China

  • 毕马威全球战略咨询 生命科学行业副总监 许宗迪

Jessica Xu, Associate Director, Global Strategy Group, KPMG

Speakers

  • Chunlin Jin (Director of Shanghai Health Development Research Center)

    Chunlin Jin

    Director of Shanghai Health Development Research Center

    Jin Chunlin, Adjunct Professor at Fudan University, Researcher, Ph.D. of University of Tokyo. Dr. Jin has been selected into the Shanghai Leading Talent Program and the State Council Special Allowance Expert. He is the current Director of Shanghai Health Development Research Center (Shanghai Medical Information Center). Dr. Jin also serves as the Vice President and Secretary General of Shanghai Health Economics Association, the Vice President of the Professional Committee of Health Management Statistics in Chinese Health Information Association. He is the chairman of the Academic Committee of the journal of Health Economics Research, and Deputy Editor-in-chief of Chinese Health Resources. He formerly served as the Director of Planning and Finance Department of Shanghai Municipal Bureau.

    view more
  • Xudong Fu (Xudong Fu, Vice GM, President of Market Access China at BMS China)

    Xudong Fu

    Xudong Fu, Vice GM, President of Market Access China at BMS China

  • Christina Cao (Executive Director, Market Access Strategy & Excellence of Astrazeneca China)

    Christina Cao

    Executive Director, Market Access Strategy & Excellence of Astrazeneca China

  • Anita Wei (Senior Director, Public Affairs & Communications, BD Greater China of BD)

    Anita Wei

    Senior Director, Public Affairs & Communications, BD Greater China of BD

    Anita Wei is the Senior Director Public Affairs & Communications for BD Greater China. She joined BD in late 2011 and is a member of BD Greater China Leadership Team as well as China Operation Committee. In this role, Anita is responsible for developing and managing BDX China level strategic programs focusing on HCW safety and patient safety, establishing and enhancing interaction with commercial and industry associations, leading China Policy Council to drive policy intelligence and corresponding strategies, and generating health economic evidence to support product market access and competitive selling. Anita is also accountable for developing strategies and actions on media relations and CSR, building corporate branding and enhancing internal communications. Anita’s team also serves as a central marketing role for BD China Key Account team, building platforms and designing programs as key enablers for KA strategy.

    Anita is now a designated delegate for AdvaMed China Executive Committee and leader for Inclusion & Diversity and WIN (Women Initiative Network) in China. Prior to joining BD, Anita served Novartis for 6 years, where her last role was Head of Communications for Novartis Pharma Greater China, reporting to the Chairman. Anita obtained her bachelor’s degree in economics from University of International Business and Economics in Beijing and her Master Degree in Marketing and Communications from University of Sydney.

    view more
  • Jessica Xu (Associate Director, Global Strategy Group of KPMG)

    Jessica Xu

    Associate Director, Global Strategy Group of KPMG

    Prior to joining KPMG, Jessica has +10 years of professional experience in life science focus in China and Asia Pacific. Jessica has worked in both corporate and consulting firms covering prescription drug, OTC, medical device and animal health. Focused in China business, she also has a one year experience covering overall Asia Pacific as countries’ functional leader.

    She has participated in +40 international and domestic projects and advised senior-management on strategic topics such as setting international growth strategies, optimizing product portfolio, pursuing mergers, acquisitions and divestitures, strengthening competitive positioning, hand-in-hand assistance in walking through product life cycle management, trouble-shooting and other performance excellence endeavours.

    view more

Tickets

A prepayment is required when choosing 'Standard Price'.

“标准票价”要求您在提交注册信息后即刻完成在线预付,若您希望在活动现场支付门票,请选择“现场票价”。
Member Ticket
Member Price Complimentary
Member Company Employee Ticket
Standard Price RMB 200
Door Price RMB 300
Non-Member Ticket
Standard Price RMB 500
Door Price RMB 600

Venue

AmCham Shanghai Conference Center

Suite 568, Shanghai Centre, 1376 Nanjing Road West
Shanghai, China

If you have any questions please contact

Contact Organizer

Show on map